FDA Approves Pfizer’s Gene Therapy Treatment for Hemophilia B
Pfizer’s BEQVEZ, a one-time gene therapy, has received FDA approval for treating adults with moderate to severe hemophilia B....
Pfizer’s BEQVEZ, a one-time gene therapy, has received FDA approval for treating adults with moderate to severe hemophilia B....
The U.S. Food and Drug Administration (FDA) has granted full approval to TIVDAK (tisotumab vedotin-tftv) for the treatment of...
A Phase 3 trial (STRIDE-10) evaluated V116, a 21-valent pneumococcal conjugate vaccine, in adults over 50. The study compared...
Vividion Therapeutics, a biopharmaceutical company, has made a significant discovery in the development of novel cancer and immune disorder...
Exegenesis Bio, a leading genetic medicines company, unveiled encouraging clinical efficacy and safety results for their EXG001-307 gene therapy...
Incyte, a renowned biopharmaceutical company, has acquired Escient Pharmaceuticals, a pioneer in developing small molecule therapeutics for immune disorders....
The international gene therapy trial for Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD) using GNT0004 has unveiled promising findings at...
Medpace Holdings reported a significant financial performance for the first quarter of 2024. Revenue soared by 17.7% to $511...
The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus...
Azitra, a biopharmaceutical company specializing in dermatology therapies, announced promising preclinical data demonstrating the potential of its platform for...